Overview
Portfolio
More
Panaceaventure
San Jose, United States
Focus on life sciences breakthroughs, incubating early‑stage companies with technologies that address unmet medical needs on a global scale.
Portfolio
37+
Employees
25+
Founded
2017
AUM
N/A
Investment focus
Stages
No stages listed
Industries
No industries listedGeographic scope
ChinaUnited States
Sources
Panaceaventure
Focus on life sciences breakthroughs, incubating early‑stage companies with technologies that address unmet medical needs on a global scale.
Portfolio
37+
Employees
25+
Founded
2017
AUM
N/A
Stages
No stages listed
Industries
No industries listedGeographic scope
ChinaUnited States
Sources
Showing 24 of 28 matched portfolio companies
Actym Therapeutics utilizes its STACT™ platform, an engineered S. Typhimurium bacterial delivery system, to locally produce and amplify therapeutic payloads for the treatment of cancer and fibrotic diseases. This approach minimizes systemic toxicity associated with traditional therapeutic administration methods while enhancing treatment efficacy at the disease site.
Funding: $59.5M
Rough estimate of the amount of funding raised
Boehringer Ingelheim Venture FundIllumina Ventures
Boehringer Ingelheim Venture FundIllumina Ventures
Funding: $59.5M
Rough estimate of the amount of funding raised
Anima is a gaming and interactive technology company that utilizes artificial intelligence and augmented reality to create immersive virtual characters and environments. Their platform enhances user engagement by transforming traditional gaming experiences into interactive, lifelike adventures.
Funding: $3.5M
Rough estimate of the amount of funding raised
Funding: $3.5M
Rough estimate of the amount of funding raised
BE Therapeutics is engineering precursor tissue that mimics embryonic brain tissue to replace damaged neocortical and spinal cord tissue, facilitating normal maturation and integration post-transplantation. This technology aims to restore lost functions in individuals affected by stroke, trauma, neurodegeneration, and aging, addressing the current lack of effective treatments for central nervous system damage.
Bio provides a digital health management platform that integrates 24/7 telemedicine services with personalized care coordination, utilizing data intelligence to enhance patient engagement and streamline healthcare delivery. The platform addresses the challenges of accessibility and continuity in healthcare by offering tailored support for chronic conditions and immediate medical assistance through a user-friendly web application.
The startup operates a diagnostic test clinic that utilizes in-depth health analysis and personalized data assessments to evaluate client longevity. By providing actionable insights and annual reassessments at an affordable cost, the company enables clients to understand their health risks and improve their long-term well-being.
50+
2K+Approximate amount of employees
Funding: $53.9M
Rough estimate of the amount of funding raised
Funding: $53.9M
Rough estimate of the amount of funding raised
The startup has developed a drug delivery platform that utilizes human cell lipids with self-identifying motifs to shield cancer-targeting viruses from neutralization by antibodies and immune cells. This technology enables precise delivery of the therapeutic virus to tumor sites, enhancing the efficacy of cancer treatment and immunotherapy.
Panacea Venture
Dogma Therapeutics is developing orally bioavailable small molecule inhibitors of PCSK9, utilizing structure-based design and high-resolution x-ray crystallography to achieve picomolar affinity. This approach targets high cholesterol and cardiovascular disease, addressing the limitations of existing monoclonal antibody therapies.
Founded 2017
Evox Therapeutics develops exosome-based therapeutics using its DeliverEX® platform to target and deliver treatments for life-threatening rare diseases with limited existing options. By engineering the natural trafficking capabilities of extracellular vesicles, Evox aims to enhance the efficacy and delivery of therapeutics in challenging medical conditions.
Funding: $165.2M
Rough estimate of the amount of funding raised
Redmile Group
Redmile Group
Funding: $165.2M
Rough estimate of the amount of funding raised
Builds software using AI agents that automate development tasks, enabling faster and more efficient creation of applications. This approach reduces manual coding efforts, streamlines workflows, and accelerates time-to-market for software projects.
Apeiron Therapeutics develops biomarker-driven small molecule therapies for cancer using structure-based, AI-driven drug design. The company focuses on creating targeted treatments for solid tumors with specific genetic deletions, addressing significant gaps in current cancer therapies.
Funding: $17.5M
Rough estimate of the amount of funding raised
Panacea Venture
Panacea Venture
Funding: $17.5M
Rough estimate of the amount of funding raised
The startup develops targeted therapies for cancer treatment through drug discovery focused on tumor immunology. By enhancing the immune response against tumors, the company aims to improve the quality of life for cancer patients.
Funding: $20.0M
Rough estimate of the amount of funding raised
Sino Biopharmaceutical
Sino Biopharmaceutical
Funding: $20.0M
Rough estimate of the amount of funding raised
HC Bioscience utilizes engineered tRNA to modify protein translation within cells, allowing for the correction of disease-causing mutations without altering DNA or mRNA. This approach enables the production of complete, functional proteins from faulty genes, addressing genetic disorders at the translational level.
Funding: $72.2M
Rough estimate of the amount of funding raised
Funding: $72.2M
Rough estimate of the amount of funding raised
Human Longevity utilizes genomic sequencing and precision diagnostics to create personalized health plans that enhance early detection and treatment of diseases. By analyzing an individual's genetic makeup and health data, the company empowers clients to proactively manage their health and extend their lifespan.
Funding: $39.8M
Rough estimate of the amount of funding raised
TVM Capital Healthcare
TVM Capital Healthcare
Funding: $39.8M
Rough estimate of the amount of funding raised
Imagene AI develops an AI-based genomic testing solution that utilizes histological data from cancer biopsies to inform personalized treatment strategies. This technology enables pharmaceutical companies and medical institutions to conduct precise molecular testing with minimal tissue samples, enhancing accessibility to tailored therapies for patients.
Funding: $21.5M
Rough estimate of the amount of funding raised
Eyal GuraLarry Ellison
Eyal GuraLarry Ellison
Funding: $21.5M
Rough estimate of the amount of funding raised
Inmagene is developing differentiated therapies for immunological and inflammatory diseases using its proprietary QuadraTek® platform, which optimizes safety and efficacy. The company targets conditions such as atopic dermatitis and alopecia areata by inhibiting the OX40/OX40L signaling pathway to improve patient outcomes.
Funding: $216.0M
Rough estimate of the amount of funding raised
Highlight CapitalPanacea Venture
Highlight CapitalPanacea Venture
Funding: $216.0M
Rough estimate of the amount of funding raised
Provides program management software designed specifically for multi-team hardware development, enabling seamless coordination across complex projects with nested hierarchies that reflect real-world systems. It addresses the challenges of task visibility, stakeholder alignment, and data security by supporting ITAR, GovCloud, and SOC II compliance, while integrating with tools like Excel, Jira, and Smartsheet for streamlined workflows.
Inven utilizes AI algorithms to analyze extensive data from various sources, enabling professionals in private equity, investment banking, and management consulting to identify high-potential companies and acquisition targets quickly. This technology significantly reduces the time spent on manual research, allowing users to source deals and gain market insights more efficiently.
Juvena Therapeutics utilizes an AI-driven platform to identify and engineer secreted proteins into biologic therapeutics that restore tissue homeostasis. The company addresses the dysregulation of protein signaling that leads to degenerative diseases, including myopathies and metabolic disorders.
Funding: $52.7M
Rough estimate of the amount of funding raised
Horizons VenturesMubadala Capital Ventures
Horizons VenturesMubadala Capital Ventures
Funding: $52.7M
Rough estimate of the amount of funding raised
Light is a financial platform that automates general ledger management, accounts receivable, and accounts payable processes for multinational companies using AI-driven analytics and real-time reporting. This solution addresses the complexities of financial operations by streamlining compliance and enhancing efficiency across diverse currencies and regulatory environments.
Lita is a Teammate-On-Demand platform that connects gamers with compatible players based on their preferred games and skill levels, facilitating collaborative gameplay and social interaction. The platform addresses the challenge of finding suitable teammates in the gaming community, enhancing the overall gaming experience in Southeast Asia and East Asia.
Provides a shared progress tracking platform for coaches and clients, enabling clients to log actions, track goals, and maintain accountability between sessions. Coaches gain measurable insights into client progress and engagement through customizable logs, reminders, and real-time feedback tools, improving the effectiveness of their practice.
Lo provides a platform for managing and automating commercial real estate leasing workflows. It centralizes lease documentation, tracks key dates, and streamlines communication between landlords and tenants. This system helps commercial property managers reduce administrative overhead and ensure compliance across their portfolio.
Funding: $1.6M
Rough estimate of the amount of funding raised
Funding: $1.6M
Rough estimate of the amount of funding raised
Myrtelle is a gene therapy company conducting clinical trials that utilize targeted gene delivery techniques to treat rare monogenic disorders. The company focuses on providing therapeutic options for patients with genetic conditions that currently have no effective treatments available.
Funding: $44.5M
Rough estimate of the amount of funding raised
Funding: $44.5M
Rough estimate of the amount of funding raised
OncXerna Therapeutics utilizes an RNA-based biomarker platform to deliver precision medicine for cancer treatment. This technology enables the identification of specific tumor characteristics, allowing for tailored therapeutic strategies that improve patient outcomes.
Showing 9 of 9 unmatched portfolio companies
Tailai Biosciences
No website provided
We don't have a full profile for this company yet.
Triarm Therapeutics
No website provided
We don't have a full profile for this company yet.
Windtree Therapeutics
No website provided
We don't have a full profile for this company yet.
Zhaoke Ophthalmology
No website provided
We don't have a full profile for this company yet.
Velavigo
No website provided
We don't have a full profile for this company yet.
Tactiva Therapeutics
No website provided
We don't have a full profile for this company yet.
XWPharma
No website provided
We don't have a full profile for this company yet.
Yizun Biotech
No website provided
We don't have a full profile for this company yet.